» Articles » PMID: 22951392

Upregulation of Osteoblastic Differentiation Marker MRNA Expression in Osteoblast-like UMR106 Cells by Puerarin and Phytoestrogens from Pueraria Mirifica

Overview
Journal Phytomedicine
Date 2012 Sep 7
PMID 22951392
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Phytoestrogens have attracted attention for their potential in the prevention of postmenopausal osteoporosis. Recently, phytoestrogen-rich herb Pueraria mirifica has been demonstrated to possess an osteogenic effect on bone in ovariectomized rats, but its underlying cellular mechanism was not known. Here, we investigated the effects of P. mirifica extract and its major isoflavone compound, puerarin, on cell viability, cell proliferation and the expression of differentiation markers in rat osteoblast-like UMR106 cells. After exposure to 17β-estradiol (E2), genistein, P. mirifica extract and puerarin, proliferation but not viability of UMR106 cells was markedly decreased. Quantitative real-time PCR revealed that P. mirifica extract and puerarin significantly increased the mRNA expression of alkaline phosphatase (ALP) and osteoprotegerin, but not Runx2, osterix or osteocalcin. Puerarin also decreased the mRNA expression of receptor activator of nuclear factor-κB ligand, an osteoclastogenic factor, suggesting that it could induce bone gain by enhancing osteoblast differentiation and suppressing osteoclast function. Furthermore, after an exposure to high affinity estrogen receptor (ER) antagonist (ICI182780), the E2-, genistein-, P. mirifica extract- and puerarin-induced upregulation of ALP expressions were completely abolished. It could be concluded that P. mirifica extract and puerarin induced osteoblast differentiation rather than osteoblast proliferation in an ER-dependent manner. The present findings, therefore, corroborated the potential benefit of P. mirifica extract and puerarin in the prevention and treatment of postmenopausal osteoporosis.

Citing Articles

Puerarin alleviates osteoporosis in rats by targeting the JAK2/STAT3 signaling pathway.

Zhao X, Zhou J, Liu Y, Wang J, Liu Y, Wang B Biomol Biomed. 2024; 24(6):1651-1661.

PMID: 38843496 PMC: 11496846. DOI: 10.17305/bb.2024.10500.


Mechanisms of action and synergetic formulas of plant-based natural compounds from traditional Chinese medicine for managing osteoporosis: a literature review.

Zhou C, Shen S, Zhang M, Luo H, Zhang Y, Wu C Front Med (Lausanne). 2023; 10:1235081.

PMID: 37700771 PMC: 10493415. DOI: 10.3389/fmed.2023.1235081.


The Relationship between Renin-Angiotensin-Aldosterone System (RAAS) Activity, Osteoporosis and Estrogen Deficiency in Type 2 Diabetes.

Mkhize B, Mosili P, Ngubane P, Sibiya N, Khathi A Int J Mol Sci. 2023; 24(15).

PMID: 37569338 PMC: 10419188. DOI: 10.3390/ijms241511963.


Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.

Xiao L, Zhong M, Huang Y, Zhu J, Tang W, Li D Aging (Albany NY). 2020; 12(21):21706-21729.

PMID: 33176281 PMC: 7695364. DOI: 10.18632/aging.103976.


Effect of Active Ingredients of Chinese Herbal Medicine on the Rejuvenation of Healthy Aging: Focus on Stem Cells.

Wang C, Ling S, Xu J Evid Based Complement Alternat Med. 2020; 2020:7307026.

PMID: 32724327 PMC: 7366228. DOI: 10.1155/2020/7307026.